You are here:

insulin aspart (Fiasp)


following an abbreviated submission:

insulin aspart (Fiasp®) is accepted for use within NHS Scotland.

Indication under review: treatment of diabetes mellitus in adults.

Insulin aspart (Fiasp®) is a new formulation with a faster onset of action than another formulation of insulin aspart and is available at an equivalent cost.

Drug Details

Drug Name: insulin aspart (Fiasp)
SMC Drug ID: 1227/17
Manufacturer: Novo Nordisk Ltd
Indication: Treatment of diabetes mellitus in adults.
BNF Category:
Sub Category: 6.1 Drugs used in diabetes
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 10 April 2017